Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
M&A activity
confidence 92%
filed 2026-07-07
EX-99.1
Perpetuals.com has signed a non-binding term sheet to explore the potential acquisition of AI Financial Corporation's subsidiary Alt5 Sigma Canada, Inc. This constitutes entry into a material acquisition transaction. Although the term sheet is non-binding and due diligence is ongoing, the announcement of a proposed acquisition of a profitable subsidiary is a material event that would affect a reasonable investor's assessment of the registrant's strategic direction and capital deployment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-07
Item 5.02
Four Leaf Acquisition Corp underwent a comprehensive governance restructuring in connection with its strategic repositioning. Three directors (Alvin Wang, Stephen Markscheid, Rahul Mewawalla) and CFO Coco Kou resigned, while three new independent directors (Nanuk Warman, Jay Izso, Mark DiSabato) were appointed to the Board and its committees, and Greg McCraw was appointed as the new CFO.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-07
Item 5.02
The disclosure centers on compensatory arrangements for David J. Enholm, the CFO: a voluntary salary reduction from $75,000 to $62,400, a waiver of accrued PTO rights, and a grant of 80,000 RSUs (40,000 vesting immediately and 40,000 upon Form 10-K filing) under the 2022 Equity Incentive Plan. While the salary reduction is voluntary, the RSU grant is material consideration for that reduction and continued service, making this fundamentally a compensation arrangement disclosure under Item 5.02(e).
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-07
The 6-K discloses results of an extraordinary general meeting held on July 6, 2026, where shareholders voted on and approved resolutions including termination of the ADR program and direct listing of Class A ordinary shares on Nasdaq. The filing reports quorum attendance (86.4 billion votes out of 138.9 billion entitled) and states "all resolutions presented to the shareholders at the Meeting were duly passed," which constitutes a shareholder vote result under Item 5.07 equivalent. This is material as it confirms shareholder approval of a significant corporate restructuring (ADR termination and direct listing).
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-07
Item 5.02
James D. Burnham resigned from his position as a Board member effective July 1, 2026. Although the filing simultaneously discloses his appointment as Director of Growth & M&A under a new employment agreement, the principal disclosed action is his departure from the Board. The resignation was uncontested and unrelated to disagreement, but Board departures are material to investor assessment of governance and leadership continuity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 1.02
The filing discloses termination of a material licensing agreement with CF Benchmarks for the Dogecoin-Dollar US Settlement Price Index, which is used daily to value the Trust's shares and calculate net asset value. The Sponsor is transitioning to FTSE as the new benchmark provider effective August 24, 2026. While this is a material operational change affecting the Trust's core pricing mechanism, it does not fit neatly into the specific taxonomy categories (not a debt covenant breach, not a general M&A activity, not a restatement). This is a material operational/strategic transition in the benchmark infrastructure supporting the ETF.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-07
EX-99.1
This is a press release announcing unaudited financial results for the first half of fiscal year 2026 (six months ended March 31, 2026). The document presents revenue, cost of revenue, gross profit, operating expenses, net loss, and liquidity metrics comparing H1 2026 to H1 2025. Although the company reported a net loss of $6.56 million and significant operational changes (transition from amusement park operator to lessor), the disclosure of interim financial results in press-release format is a classic earnings_release event. The material nature is confirmed by substantial revenue decline (48.24%), impairment charges, and strategic asset sales disclosed in subsequent events.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
The filing discloses termination of a material benchmark licensing agreement with CF Benchmarks (effective August 31, 2026) and transition to a new licensing agreement with FTSE International Limited (expected August 24, 2026). The Pricing Benchmark is used daily to value the Trust's shares and calculate net asset value, making this operational change material to the ETF's functioning. This is a material contract transition rather than a financial obligation event, covenant breach, or other specific category.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-07
Item 1.01
Osprey Acquisition Corp. III consummated its initial public offering on July 2, 2026, raising $300.15 million in gross proceeds through the issuance of 30,015,000 units at $10.00 per unit. Each unit comprises one Class A ordinary share and one-third of a redeemable warrant exercisable at $11.50. The IPO establishes the capital base for the SPAC's future business combination activities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-07
Item 3.02
Concurrent with the IPO, Osprey Acquisition Corp. III completed a private placement of 747,000 Units at $10.00 per unit, generating $7.47 million in gross proceeds. The units were purchased by Cantor Fitzgerald (261,000 units) and sponsor Osprey Acquisition Sponsor III, LLC (486,000 units) pursuant to Section 4(a)(2) exemption from registration.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-07
Item 5.02
On June 30, 2026, seven directors—Daniel C. Herz, Jonathan Z. Cohen, Edward E. Cohen, Jeffrey Clifford, Brian L. Frank, Atul Khanna, and Jeffrey Kupfer—were appointed to the board in connection with the IPO, with specific committee assignments established to govern the newly public blank-check company.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 1.02
The filing discloses termination of the CME CF XRP—Dollar Reference Rate licensing agreement with CF Benchmarks effective August 31, 2026, and transition to a new benchmark provider (FTSE) on or about August 24, 2026. This is a material operational change because the Pricing Benchmark is used to value the Trust's shares daily and calculate net asset value. While Item 1.02 typically covers M&A terminations, this disclosure centers on a critical operational transition in the Trust's pricing infrastructure rather than a business combination or disposition, making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 1.02
The filing discloses termination of the CME CF Bitcoin Reference Rate licensing agreement effective August 31, 2026, and a planned transition to FTSE as the new benchmark provider for calculating the Trust's net asset value. While Item 1.02 typically covers material definitive agreements, this is fundamentally an operational change to the Trust's pricing infrastructure rather than a traditional M&A or financial obligation event. The transition is material because the benchmark is used daily to value the Trust's shares, but it does not fit the specific categories of debt issuance, covenant breach, or acquisition activity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
The filing discloses termination of a material benchmark licensing agreement with CF Benchmarks (effective August 31, 2026) and transition to a new licensing agreement with FTSE International Limited (expected August 24, 2026). The Pricing Benchmark is used daily to value the Trust's shares and calculate net asset value, making this operational change material to the ETF's functioning. This is a material contract transition rather than a financial obligation event (debt_issuance) or M&A activity, so operational_other best fits.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 1.02
The filing discloses termination of a material licensing agreement with CF Benchmarks for the CME CF Solana-Dollar Reference Rate, which is used daily to value the Trust's shares and calculate net asset value. The Sponsor is transitioning to FTSE as the new benchmark provider effective August 24, 2026. While this is a material operational change affecting the ETF's core valuation mechanism, it does not fit neatly into specific categories like debt_issuance, ma_activity, or covenant_breach; it is a strategic operational transition in benchmark provider that would affect investor assessment of the fund's operations.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 1.02
The filing discloses termination of a material benchmark licensing agreement with CF Benchmarks (effective August 31, 2026) and transition to a new licensing agreement with FTSE International Limited. The Pricing Benchmark is used daily to value the Trust's shares and calculate net asset value, making this operational change material to the ETF's functioning. While Item 1.02 typically covers M&A terminations, this is a service provider transition affecting the Trust's core operational infrastructure rather than a business combination or acquisition termination.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Evolution Metals announced execution of a supply contract with Senri Trading Co., Ltd. for neodymium-praseodymium (NdPr) metal from a non-China source to support its rare earth magnet production operations targeting 10,000 metric tons per annum. This is a material operational/strategic event—a significant supply agreement enabling the company's production expansion and compliance with upcoming DFARS 252.225-7052 restrictions on Chinese-origin rare earth magnets in U.S. defense systems (effective January 1, 2027). While not a merger, acquisition, or specific financial obligation, the supply contract is a critical operational milestone for the company's business strategy and capacity utilization.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-07
This 8-K discloses the consummation of a $230 million initial public offering by Viking Acquisition Corp. II on July 6, 2026, including entry into multiple material definitive agreements (underwriting agreement, warrant agreements, insider letter agreement, registration rights agreement, and indemnity agreements). While the primary event is an IPO capital raise, the filing is structured around Item 1.01 (Entry into Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), which are financial/capital events. However, the core transaction—a blank-check SPAC raising capital to pursue a future business combination—is most appropriately classified as a material capital/financing event. The closest taxonomy fit is `ma_activity` given the material nature of the IPO and the company's stated purpose to effect a merger or business combination, though this is technically a capital raise rather than an M&A transaction itself.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-07
Item 5.02
Seth Demsey was appointed as co-Chief Executive Officer of Corvex, Inc., effective July 1, 2026, following the Annual Meeting. This appointment represents a material change in the Company's executive leadership.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-07
Item 5.07
Corvex held its Annual Meeting on July 1, 2026, with shareholders voting on seven matters: election of three directors (Jay Crystal, Patrick Fleury, and Nicholas Donofrio), approval of equity issuances related to a merger (Conversion Proposal and RSU/option vesting), ratification of BDO USA as auditor, approval of the 2026 Equity Incentive Plan and Employee Stock Purchase Plan, and authorization to adjourn the meeting. All matters were approved.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-07
Item 8.01
Following stockholder approval, Series C Preferred Stock automatically converted into common stock, and Series D Preferred Stock was voluntarily converted into 4,752,244 shares of common stock, increasing common share count to 27,635,745 shares outstanding with additional Series D convertible into 28,929,592 shares. These conversions materially dilute existing common shareholders' ownership and voting power.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 1.01
NorthStrive Defense Tech, a wholly owned subsidiary of PMGC Holdings, entered into an exclusive license agreement for aerospace and defense technologies covering U.S. Patent No. 12,291,334 and associated know-how. While Item 1.01 typically covers M&A activity, this is a material strategic licensing arrangement that grants exclusive rights to develop and commercialize products in a defined field, with ongoing royalty obligations and diligence milestones. This is a material operational/strategic contract rather than a traditional acquisition or merger, making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-07
Item 2.01
House of Doge Inc. completed its merger with Brag House Holdings, Inc. (formerly NASDAQ: TBH) on June 30, 2026, resulting in a material change of control. The combined company was renamed House of Doge Inc., began trading under ticker 'HODO' on Nasdaq on July 1, 2026, with former HOD stockholders owning approximately 90.66% of issued and outstanding shares (83.32% on a fully diluted basis).
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-07
EX-99.1
The press release announces three material executive and board leadership appointments: Tulani Sikwila as Chairman (in addition to CEO), Wendy Luhabe as Independent Non-Executive Director and Lead Independent Director, and Sphe Mchunu as Chief Financial Officer. These are discrete appointments of named executives and directors to key governance and operational roles, with Mchunu's transition from General Counsel to CFO being particularly significant for financial leadership during the company's growth phase and mine restart execution.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 8.01
The disclosure centers on a non-binding letter of intent from Elko Heat Company to provide up to $40 million in joint development capital to support ACRG's pursuit of a BLM Solar Energy Zone competitive lease and solar development at the Millers Property in Nevada. While this involves capital commitment, it is explicitly non-binding and subject to multiple closing conditions (due diligence, investment committee approval, BLM authorization, definitive documentation). The event is primarily operational/strategic—a partnership and development opportunity—rather than a binding financial obligation (debt_issuance) or M&A activity. The materiality is high given the $40 million capital commitment and strategic importance to the company's energy infrastructure thesis, though the non-binding nature and contingencies temper certainty.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-07
Item 5.02
Chi Special Acquisition Corp. appointed two new directors, Chung Fu Wing and Shangwei Chen, effective June 2, 2026, to fill board vacancies. The appointments include detailed biographical information and represent a material change to board composition.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-07
EX-99.1
The Company received a Nasdaq notification dated July 1, 2026, that it failed to maintain the minimum bid price of US$1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The Company has 180 calendar days (until December 28, 2026) to regain compliance or faces potential delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 2.01
CareDx completed two material M&A transactions: (1) sale of CareDx AB and lab products business to Eurobio Scientific for $171.7 million cash on June 30, 2026, and (2) acquisition of Naveris, Inc. for $161.8 million cash plus up to $100 million in contingent consideration on July 1, 2026. These transactions materially reshape CareDx's business portfolio by divesting its European lab products business while acquiring a high-growth specialty oncology diagnostics platform (NavDx) that expands the addressable market to $12+ billion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 2.01
The filing discloses the completed sale of the 357-room Marriott Fremont Silicon Valley hotel for $53.0 million in cash on July 1, 2026, pursuant to an Agreement of Purchase and Sale dated June 19, 2026. This is a material disposition of a hotel asset by Ashford Hospitality Trust, a REIT, and is properly classified under Item 2.01 (Completion of Acquisition or Disposition of Assets). The transaction is material to investors as it represents a significant reduction in the company's asset base and includes pro forma financial statements showing the removal of the property's revenue and expenses.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-07
Item 5.02
Jerome T. Upton, the Company's Executive Vice President and Chief Financial Officer, has been appointed Interim President and Chief Executive Officer effective July 7, 2026. While the filing also discloses that CEO Thomas J. McInerney is taking a temporary leave of absence for health reasons, the principal disclosed action is Upton's appointment to the interim CEO role. This is material as it represents a change in the principal executive officer position, even though it is temporary and the incumbent CEO is on leave rather than departing permanently.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-07
EX-99.1
This is a news release announcing the voting results from DeFi Technologies' 2026 Annual and Special Meeting of shareholders held on June 29, 2026. The disclosure reports detailed election results for six director nominees, approval of auditors (92.276% in favour), approval of a share consolidation (73.271% in favour), approval of an Amendment to By-Law No. 1 (90.420% in favour), and approval of an Advance Notice By-Law No. 2 (64.279% in favour). These are material shareholder votes that affect governance and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-07
Item 5.07
This is a clear disclosure of shareholder vote results from a Special Meeting held on July 7, 2026. The filing reports the final voting tallies on Proposal 1 to renew authorization for the Company to sell shares below net asset value, with specific vote counts (For: 277,640,199; Against: 63,873,735; Abstained: 7,460,523). This is a material governance event affecting the Company's capital-raising authority and is properly classified under Item 5.07.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-07-07
The 6-K furnishes a closing notice for the public offering and issuance of R$ 1,000,000,000.00 (one billion reais) in simple debentures (non-convertible bonds) by AXIA Energia S.A., the 9th issuance of such debentures. The document confirms completion of the offering on June 15, 2026, with 1,000,000 debentures subscribed and paid in. This constitutes creation of a new direct financial obligation and is material to investors assessing the registrant's capital structure and leverage.
View raw filing on EDGAR →
8-K
Legal Other
confidence 85%
filed 2026-07-07
Item 8.01
The disclosure centers on an FDA Warning Letter issued to IMS (a subsidiary) on July 2, 2026, citing CGMP violations at its South El Monte manufacturing facility. This is a regulatory enforcement action that could materially impact the company's ability to manufacture and distribute products. While the Warning Letter does not currently direct cessation of production, the company acknowledges uncertainty about FDA satisfaction with remediation efforts and the possibility of "additional regulatory or legal action" without further notice, creating material regulatory and operational risk.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 8.01
Axos Financial entered into a definitive agreement to acquire Arc Technologies, Inc., a financial technology platform. This is a material acquisition disclosed under Item 8.01 (Other Events). Although the company states the transaction is "not expected to have a material impact to results of operations or financial condition," the entry into a definitive agreement for an acquisition is itself a material event that would affect a reasonable investor's assessment of the registrant's strategic direction and capital deployment. The press release emphasizes Arc's AI capabilities, technology platform, and strategic fit with Axos' digital banking strategy.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The Federal Home Loan Bank of Des Moines discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes. Schedule A lists specific debt securities committed to be issued on trade dates in July 2026, with principal amounts totaling approximately $135 million across multiple bond tranches with varying maturities (2028–2036), coupons (4.50%–5.10%), and call features. This is a classic debt issuance disclosure under Item 2.03, material to the Bank's capital structure and funding operations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Topeka. Schedule A details four specific debt issuances with trade dates in July 2026, totaling approximately $835 million in principal across fixed-rate and variable-rate instruments with maturities ranging from 2026 to 2031. This is a classic debt_issuance event under Item 2.03, material to investors assessing the registrant's capital structure and funding activities.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Pittsburgh. Schedule A itemizes six specific debt issuances with trade dates in July 2026, ranging from $5 million to $500 million in principal amount, with maturities from 2027 to 2041. This is a classic debt_issuance event under Item 2.03, material to investors assessing the registrant's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Boston. Schedule A details four specific debt issuances with trade dates in July 2026, totaling approximately $640 million in principal, with maturity dates ranging from October 2026 to July 2029. This is a classic debt_issuance event under Item 2.03, disclosing new direct financial obligations created by the registrant.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the issuance of consolidated obligation bonds totaling $475 million (125M + 350M) by the Federal Home Loan Bank of Atlanta on trade date 7/1/2026, settling 7/6/2026 with maturity 10/6/2026. This represents a direct creation of financial obligations under Item 2.03, and the Bank explicitly states that "consolidated obligations issuance is material to the Bank." The detailed Schedule A provides specific terms including CUSIP, settlement, maturity, and rate structure for these debt securities.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds with a par value of $10,000,000, maturing 7/2/2031 at a 4.360% coupon, settled on 7/7/2026. This is a direct creation of a financial obligation under Item 2.03, constituting a debt issuance. The disclosure includes specific bond terms (CUSIP, maturity date, coupon rate, call provisions), which are hallmarks of debt creation disclosures.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-07
Item 2.03
The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds by the Federal Home Loan Bank of Dallas. Schedule A details two bond issuances with trade dates of 7/1/2026, totaling $30 million in par amount, with maturity dates in 2028 and 2030 respectively. This is a routine debt issuance disclosure under Item 2.03, which is material to investors as it represents new financial obligations of the registrant.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-07-07
Item 8.01
The disclosure centers on shareholder approval of a dividend waiver aggregating up to $1.27 per share over twelve months. While technically a waiver (non-declaration) rather than a declaration, the event is material to investors as it affects capital allocation and shareholder returns. The 59% voting threshold and 97% approval rate indicate significant shareholder engagement on a capital decision. The MHC's 81% control and pending Federal Reserve approval add governance and regulatory dimensions, but the core event is the dividend decision itself.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-07
EX-99.1
This press release announces receipt of official FDA End-of-Phase 2 meeting minutes confirming a registrational pathway for ATH434 in Multiple System Atrophy, including FDA agreement on Phase 3 trial design and the possibility of approval based on a single pivotal trial plus confirmatory evidence. This is a material regulatory and clinical development milestone that advances the company's lead drug candidate toward potential NDA filing, but it is not a discrete event type in the taxonomy (not M&A, not an earnings release, not an executive change, not a restatement or going-concern issue). It represents a significant operational/strategic advancement in the drug development program that would affect a reasonable investor's assessment of the company's prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-07
Item 8.01
Vaxart announced topline 12-month safety data from a Phase 2b clinical trial of its oral COVID-19 vaccine candidate, showing no vaccine-related serious adverse events or sustained Grade 3+ adverse events in either arm. This is a material clinical milestone for a clinical-stage biotech company, but it does not fit the specific categories of earnings_release (no financial results), material_litigation, or other named event types. The disclosure represents a significant operational/clinical development that would affect investor assessment of the company's vaccine program progress.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-07
Item 8.01
The filing discloses the completion of a merger between Envirotech Vehicles and Azio AI Corporation, closed on July 2, 2026. The press release explicitly states "the successful completion of its merger with Azio AI Corporation" and describes the transaction structure, merger consideration (2,655,157 shares of common stock and 973,450 shares of preferred stock), and the combined company's strategic pivot to AI infrastructure. This is a material acquisition that fundamentally transforms the registrant's business and capital structure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-07
Item 7.01
BIO-key's disclosure announces the reinstatement of trading on Nasdaq Capital Market following a June 16th hearing where the Nasdaq Hearings Panel determined the Company "has regained compliance with the continued listing standards, including minimum bid price and SEC filing requirements." This directly addresses a delisting risk event—the company had previously been subject to a trading halt due to non-compliance with listing standards and has now resolved that issue. The materiality is clear: trading suspension and reinstatement materially affect investor access to the stock and the company's market standing.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-07-07
Item 5.02
Lori M. Toomey, a Board member and Executive Committee member, has determined not to stand for re-election at the 2027 annual meeting, constituting a planned departure from her director role.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 72%
filed 2026-07-07
Item 7.01
The Toomey Directors' decision not to extend or renew the Toomey Loan (maturing December 31, 2026, with $365,000 principal and $9,191 accrued interest) creates a material liquidity crisis, with risk of cascading defaults on senior secured debt if the Company cannot refinance the obligation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-07
Aptera announced receipt of an EPA Certificate of Conformity for its 2026 Launch Edition vehicle on June 18, 2026. The filing describes this as "an important federal emissions compliance milestone" and "one of the two primary federal certifications required before a vehicle can be legally sold in the United States." This is a material operational and regulatory milestone for a pre-revenue automotive manufacturer advancing toward commercialization, though it does not fit the specific categories of earnings, M&A, impairment, litigation, or other named event types.
View raw filing on EDGAR →